

Hemovigilance Module Monthly Reporting Denominators

*Required for saving

*Facility ID#: *Mon		*Month:		*Year:	· · · · · · · · · · · · · · · · · · ·
Table 1					
Products			*Units Transfused	*Aliquots Transfused	*Total Discards
Whole Blood		TOTAL TOTAL			
Red blood cells	Whole blood derived	Not irradiated or leukocyte reduced Irradiated			
		Leukocyte reduced Irradiated and leukocyte reduced			
		TOTAL Not irradiated or leukocyte reduced			
	Apheresis	Irradiated Leukocyte reduced			
		Irradiated and leukocyte reduced			l
Platelets	Whole blood	Not irradiated or leukocyte reduced Irradiated			
	derived	Leukocyte reduced Irradiated and leukocyte reduced			
		TOTAL			
	Apheresis	Not irradiated or leukocyte reduced Irradiated			
		Leukocyte reduced Irradiated and leukocyte reduced			
Plasma	Total whole blood derived				
(all types) Total apheresis					
Cryoprecipitate					

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.303 Rev. 6, v9.2

Public reporting burden of this collection of information is estimated to average 70 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).



Hemovigilance Module Monthly Reporting Denominators

*Does your facility transfuse blood products treated with pathogen reduction technology?	Yes	No
^If yes, then complete Table 2.		

Table 2

Products			Units Transfused	Aliquots Transfused	Total Discards
Red blood	Whole	TOTAL			
	blood	S-303-treated			
	derived	Riboflavin-treated			
cells		TOTAL			
	Apheresis	S-303 -treated			
		Riboflavin-treated			
	Whole	TOTAL			
	blood	Psoralen-treated			
Platelets	derived	Riboflavin-treated			
Fialeiels		TOTAL			
	Apheresis	Psoralen-treated			
		Riboflavin-treated			
	Whole	TOTAL			
	blood	Psoralen-treated			
Plasma	derived	Riboflavin-treated			
(all types)	Apheresis	TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
Cryoprecipitate		TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
		Pathogen Reduction			
		Cryoprecipitated Fibrinogen Complex			

^If your facility transfused pathogen reduced apheresis platelets (e.g., the apheresis platelet total in table 2 is greater than 0), then complete Table 3.

Table 3

Products			Units Transfused	Aliquots Transfused	Total Discards
Platelets	Apheresis	Psoralen-treated			
		Psoralen-treated and in Plasma			
		Psoralen-treated and in Platelet additive solution			
		Riboflavin-treated			
		Riboflavin-treated and in Plasma			
		Riboflavin-treated and in Platelet additive solution			

*Patient samples collected for type and screen or crossmatch: ______

*Total crossmatch procedures: _____

Total patients transfused: _____



Hemovigilance Module Monthly Reporting Denominators

Custom Fields					
Label		Label			